spironolactone has been researched along with Vascular Diseases in 12 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 7.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 6.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 3.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 2.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luther, JM | 1 |
| Luo, P | 1 |
| Wang, Z | 1 |
| Cohen, SE | 1 |
| Kim, HS | 1 |
| Fogo, AB | 1 |
| Brown, NJ | 1 |
| Brem, AS | 1 |
| Nitta, K | 1 |
| Akiba, T | 1 |
| Nihei, H | 1 |
| GRIEBLE, HG | 2 |
| JOHNSTON, LC | 2 |
| FULLER, JB | 1 |
| Dawson, A | 1 |
| Davies, JI | 1 |
| Struthers, AD | 1 |
| Nehme, J | 1 |
| Mercier, N | 1 |
| Labat, C | 1 |
| Benetos, A | 2 |
| Safar, ME | 2 |
| Delcayre, C | 1 |
| Lacolley, P | 2 |
| Van Vliet, AA | 1 |
| Kröger, R | 1 |
| Dubbelman, R | 1 |
| Ten Bokkel-Huinink, WW | 1 |
| Rocha, R | 1 |
| Stier, CT | 1 |
| Kifor, I | 1 |
| Ochoa-Maya, MR | 1 |
| Rennke, HG | 1 |
| Williams, GH | 1 |
| Adler, GK | 1 |
| Ferenczy, I | 1 |
| Loránt, I | 1 |
| Péter, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493] | Phase 3 | 33 participants (Actual) | Interventional | 2014-11-07 | Completed | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for spironolactone and Vascular Diseases
| Article | Year |
|---|---|
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; | 2004 |
1 trial available for spironolactone and Vascular Diseases
| Article | Year |
|---|---|
Treatment of patients with IVCS and gross oedema and ascites with diuretic combination and ACE-inhibitors: relation to baseline PRA and PAC.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Ascites; Captopril; Diuretics; D | 1995 |
10 other studies available for spironolactone and Vascular Diseases
| Article | Year |
|---|---|
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D | 2012 |
Targeting activated mineralocorticoid receptor: Occam's razor revisited.
Topics: Aldosterone; Angiotensin II; Animals; Heart Diseases; Kidney Diseases; Mineralocorticoid Receptor An | 2012 |
Aldosterone blockade and vascular calcification in hemodialysis patients.
Topics: Administration, Oral; Animals; Calcinosis; Eplerenone; Humans; Kidney Failure, Chronic; Male; Middle | 2003 |
Treatment of arterial hypertensive disease with diuretics. II. Effects on electrolytes and uric acid of bendroflumethiazide, potassium chloride, and spironolactone.
Topics: Bendroflumethiazide; Diuretics; Electrolytes; Humans; Hypertension; Potassium Chloride; Spironolacto | 1962 |
Treatment of arterial hypertensive disease with diuretics. I. Effects on blood pressure of bendroflumethiazide, potassium chloride, and spironolactone.
Topics: Bendroflumethiazide; Blood Pressure; Blood Pressure Determination; Diuretics; Humans; Hypertension; | 1962 |
Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone.
Topics: Animals; Aorta; Blood Pressure; Blotting, Northern; Carotid Artery Diseases; Collagen; Eplerenone; F | 2006 |
Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Collagen; Fibrosis; Heart Rate; Hypertension; Isoquinoline | 1997 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Idiopathic oedema.
Topics: Adrenal Glands; Aldosterone; Diuretics; Edema; Female; Gonadal Steroid Hormones; Humans; Plasma Volu | 1972 |
Stenosis of the inferior vena cava with secondary hyperaldosteronism.
Topics: Angiography; Body Weight; Constriction; Diuresis; Diuretics; Edema; Humans; Hyperaldosteronism; Infa | 1969 |